BR112022018043A2 - Composições farmacêuticas de sais de éster de colina de ácido lipoico e métodos de tratamento usando as mesmas - Google Patents

Composições farmacêuticas de sais de éster de colina de ácido lipoico e métodos de tratamento usando as mesmas

Info

Publication number
BR112022018043A2
BR112022018043A2 BR112022018043A BR112022018043A BR112022018043A2 BR 112022018043 A2 BR112022018043 A2 BR 112022018043A2 BR 112022018043 A BR112022018043 A BR 112022018043A BR 112022018043 A BR112022018043 A BR 112022018043A BR 112022018043 A2 BR112022018043 A2 BR 112022018043A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
same
lipoic acid
ester salts
choline ester
Prior art date
Application number
BR112022018043A
Other languages
English (en)
Inventor
Bucher Christoph
Flubacher Dietmar
Douglas Foutch Jeremiah
Ghosh Malay
Franz Kluge Johannes
Li Zaixing
Ry Mcalister Cale
Murlidhar Waykole Liladhar
Soren WORTHMANN Jens
Zhu Tingying
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022018043A2 publication Critical patent/BR112022018043A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A presente invenção refere-se a sais de éster de colina de ácido lipoico (LACE), suas formas cristalinas e métodos de uso dos mesmos. A presente divulgação fornece adicionalmente composições farmacêuticas de sais de LACE e métodos de uso dos mesmos.
BR112022018043A 2020-03-13 2021-03-12 Composições farmacêuticas de sais de éster de colina de ácido lipoico e métodos de tratamento usando as mesmas BR112022018043A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020079271 2020-03-13
US202063013836P 2020-04-22 2020-04-22
PCT/IB2021/052092 WO2021181361A1 (en) 2020-03-13 2021-03-12 Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same

Publications (1)

Publication Number Publication Date
BR112022018043A2 true BR112022018043A2 (pt) 2022-10-18

Family

ID=75108681

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018043A BR112022018043A2 (pt) 2020-03-13 2021-03-12 Composições farmacêuticas de sais de éster de colina de ácido lipoico e métodos de tratamento usando as mesmas

Country Status (18)

Country Link
US (2) US11135239B1 (pt)
EP (1) EP4118079A1 (pt)
JP (2) JP7041298B2 (pt)
KR (1) KR20220146561A (pt)
CN (2) CN113387923A (pt)
AU (1) AU2021235563A1 (pt)
BR (1) BR112022018043A2 (pt)
CA (1) CA3175077A1 (pt)
CO (1) CO2022012653A2 (pt)
CR (1) CR20220449A (pt)
DO (1) DOP2022000179A (pt)
EC (1) ECSP22069611A (pt)
IL (1) IL295378A (pt)
JO (1) JOP20220211A1 (pt)
MX (1) MX2022011206A (pt)
PE (1) PE20230242A1 (pt)
TW (1) TWI768760B (pt)
WO (1) WO2021181361A1 (pt)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520920A (en) 1978-07-31 1980-02-14 Honda Motor Co Ltd Device for absorbing twisting vibration of drive system
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8795706B2 (en) 2000-08-16 2014-08-05 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
WO2010147962A1 (en) 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
KR20160145558A (ko) * 2014-03-03 2016-12-20 앙코르 비전, 인코포레이티드 리포산 콜린 에스테르 조성물 및 사용 방법
WO2016126662A1 (en) 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
CA3022351A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
JP6889165B2 (ja) * 2015-09-24 2021-06-18 ノバルティス アーゲー リポ酸コリンエステル組成物および生体適合性眼用製剤の作製方法
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
CN107089967A (zh) 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN106967044B (zh) 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
RU2020122659A (ru) * 2018-02-05 2022-03-09 Целликсбио Прайвет Лимитед Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения
US11158871B2 (en) 2018-07-18 2021-10-26 GM Global Technology Operations LLC Fuel cell assembly and a vehicle that utilizes the fuel cell assembly
US11985964B2 (en) 2018-08-03 2024-05-21 Kevin F Lohmeier Fishing rod holder
CN108586429A (zh) 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法
CN108822077A (zh) 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法

Also Published As

Publication number Publication date
CN113387923A (zh) 2021-09-14
CR20220449A (es) 2022-10-12
CN115279745A (zh) 2022-11-01
KR20220146561A (ko) 2022-11-01
AU2021235563A1 (en) 2022-09-22
TW202140435A (zh) 2021-11-01
JP2022058376A (ja) 2022-04-12
JP2021147392A (ja) 2021-09-27
TWI768760B (zh) 2022-06-21
US20210283171A1 (en) 2021-09-16
CA3175077A1 (en) 2021-09-16
US11135239B1 (en) 2021-10-05
PE20230242A1 (es) 2023-02-07
US20210393671A1 (en) 2021-12-23
IL295378A (en) 2022-10-01
MX2022011206A (es) 2022-09-19
ECSP22069611A (es) 2022-10-31
US11590158B2 (en) 2023-02-28
WO2021181361A1 (en) 2021-09-16
JOP20220211A1 (ar) 2023-01-30
DOP2022000179A (es) 2022-09-30
CO2022012653A2 (es) 2022-09-09
JP7041298B2 (ja) 2022-03-23
EP4118079A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
BR112023016299A2 (pt) Composições e métodos para inibir kras
EA201992247A1 (ru) Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112021002267A8 (pt) Inibidores de prmt5
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
BR112017012197A2 (pt) composto, composição herbicida, mistura herbicida e método para controlar o crescimento de vegetação indesejada
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
BR112017009651A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
BR112022022608A2 (pt) Compostos como inibidores de bcl-2
BR112017026406A2 (pt) formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico
UY33270A (es) Sales cristalinas de un potente inhibidor del hcv
BR112017023959A2 (pt) novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus
BR112018004234A2 (pt) método para produçao de ésteres de cianidrina contendo fósforo
BR112022006279A2 (pt) Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
CO2021011042A2 (es) Sales de sulcardina
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
BR112018004247A2 (pt) método para produção de ésteres de cianidrina contendo fósforo.
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
CL2021001640A1 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
BR112022012368A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2
BR112022018043A2 (pt) Composições farmacêuticas de sais de éster de colina de ácido lipoico e métodos de tratamento usando as mesmas
BR112022026896A2 (pt) Método para a preparação de aminofuranos
BR112023022298A2 (pt) Moduladores de trex1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]